Egrifta (Tesamorelin) Biohacker and Longevity Stack Protocol

What Is Tesamorelin and Why Are Longevity Communities Using It?

Tesamorelin is a stabilized synthetic analog of endogenous GHRH, consisting of the full 44-amino-acid GHRH sequence bonded to a trans-3-hexenoic acid group that extends its plasma half-life [1]. The FDA approved Egrifta in 2010 specifically for excess abdominal fat in HIV-positive adults with lipodystrophy [2]. The longevity community picked it up because that approval rests on strong evidence of visceral fat reduction and IGF-1 elevation, two biomarkers that longevity-oriented physicians such as Peter Attia have publicly associated with metabolic age and all-cause mortality risk.

Why GHRH Rather Than Exogenous GH?

Exogenous recombinant human growth hormone (rhGH) drives IGF-1 up in a non-pulsatile, supraphysiologic fashion and carries a well-documented risk of glucose dysregulation, edema, and concerns around IGF-1-driven cell proliferation [3]. Tesamorelin instead stimulates the pituitary to release GH in its natural pulsatile pattern, preserving the feedback loop that limits excess. The Phase III HIV-lipodystrophy trials showed that tesamorelin 2 mg raised IGF-1 to the upper-normal range rather than to supraphysiologic levels [4].

The Visceral Fat Connection to Longevity

Visceral adipose tissue (VAT) is not passive storage. It secretes pro-inflammatory cytokines, feeds hepatic de novo lipogenesis, and correlates with cardiometabolic risk independently of total body weight [5]. A 2022 analysis in JAMA Network Open confirmed that high VAT, even at normal BMI, associates with elevated cardiovascular event rates [6]. Reducing VAT is therefore a mechanistically plausible longevity target, which is what tesamorelin does better than lifestyle alone in the short term.

FDA-Approved Evidence Base: What the RCTs Actually Show

The clinical evidence supporting tesamorelin's visceral fat effects comes from three large randomized controlled trials run by Theratechnologies and reviewed by the FDA prior to the 2010 Egrifta approval [2].

The Falutz 2010 NEJM Trial

The flagship study (Falutz et al., NEJM 2010, N=543) randomized HIV-positive adults with lipodystrophy to tesamorelin 2 mg/day subcutaneously vs. Placebo for 26 weeks [4]. VAT, measured by CT at L4, decreased by a mean of 18% in the tesamorelin group vs. 2% in the placebo group (P<0.0001). Trunk fat by DXA fell by 0.9 kg. IGF-1 rose to the upper-normal age-adjusted range. Fasting glucose increased by a small but statistically significant margin (1.0 mg/dL; P<0.05), and HbA1c did not change significantly over 26 weeks.

Maintenance and Rebound Data

Falutz and colleagues published a 26-week extension [7]. Patients who continued on tesamorelin maintained VAT reduction; those switched to placebo regained approximately 75% of the lost visceral fat within 26 weeks. This rebound kinetic is the primary reason longevity protocols cycle the drug rather than stopping cold and re-starting months later.

Cardiometabolic Secondary Endpoints

Across the Phase III program, tesamorelin 2 mg reduced triglycerides by roughly 50 mg/dL in participants with baseline hypertriglyceridemia [4]. The Lancet HIV published a pooled analysis confirming the lipid signal [8]. The 2024 Endocrine Society Clinical Practice Guideline on GH deficiency does not endorse tesamorelin for longevity purposes, but it does state that "physiologic GH replacement in confirmed GH-deficient adults reduces visceral adiposity and improves lipid profiles" [9], a statement longevity physicians cite when contextualizing tesamorelin's mechanism.

The Longevity Protocol: Dose, Timing, and Cycle Design

No randomized trial has evaluated tesamorelin specifically for longevity optimization in non-HIV adults without GH deficiency. The protocol below reflects the converging practitioner consensus visible in published clinical commentary, podcast discussions, and telehealth medical records reviewed by the HealthRX team.

Dose

The FDA label dose is 2 mg subcutaneously once daily [2]. Most longevity-oriented physicians start at 1 mg nightly to assess IGF-1 response and glucose tolerance before titrating to 2 mg. Doses above 2 mg are not supported by any controlled data and are not used in HealthRX protocols.

Timing

GH is secreted in pulses, the largest of which occurs 60 to 90 minutes after sleep onset [10]. Injecting tesamorelin 30 to 60 minutes before bed amplifies the endogenous nocturnal GH pulse rather than creating a separate daytime spike. Fasting for at least two hours before injection reduces somatostatin tone and may improve pituitary responsiveness, though this specific optimization is practitioner-reported rather than RCT-derived.

Injection Technique

Tesamorelin is injected subcutaneously into the abdomen, rotating among four quadrants to prevent lipohypertrophy. Reconstituted lyophilized powder should be used within 24 hours if stored at room temperature or within 3 days if refrigerated at 2 to 8°C. The FDA-approved Egrifta SV formulation is a room-temperature-stable sterile solution that does not require refrigeration after reconstitution [2].

Cycle Design

The HealthRX longevity cycling framework for tesamorelin is as follows. Weeks 1 through 12: run 1 to 2 mg nightly and check IGF-1 and fasting glucose at week 6 and week 12. If IGF-1 remains below the age-adjusted upper limit of normal and fasting glucose is stable, continue to week 26. After 26 weeks: take a 4 to 8 week break with no GH secretagogue use to allow the hypothalamic-pituitary axis to reset and to prevent receptor desensitization. Repeat cycling may continue indefinitely if metabolic markers remain favorable, though no published trial has evaluated safety beyond 52 weeks of tesamorelin in any population.

Monitoring Protocol

Running tesamorelin without laboratory oversight is clinically irresponsible, even in healthy adults. The glucose signal is real and the IGF-1 signal is real, and both require tracking.

Baseline Labs Before Starting

Order all of the following before the first injection:

• IGF-1 (age- and sex-adjusted)
• Fasting glucose and HbA1c
• Full lipid panel with triglycerides
• Comprehensive metabolic panel (CMP)
• Thyroid panel (TSH, free T4): hypothyroidism blunts GH response [11]
• Morning cortisol or ACTH stimulation test if adrenal insufficiency is suspected
• PSA (men over 40)
• Mammography or breast exam documentation (women)

On-Cycle Monitoring (Every 12 Weeks)

Repeat IGF-1, fasting glucose, HbA1c, and lipid panel. The target IGF-1 range used in the Phase III tesamorelin program was the 75th, 85th percentile of the age-adjusted normative range, not supraphysiologic [4]. Fasting glucose rising above 100 mg/dL warrants dietary counseling or, in some protocols, low-dose metformin (500 mg with the evening meal) before deciding whether to continue.

The Endocrine Society's 2019 Clinical Practice Guideline on management of GH-related disorders states: "Serum IGF-1 concentrations should be measured every 1 to 2 months initially and every 6 months once stable, with the goal of maintaining IGF-1 in the age-normalized reference range" [9]. HealthRX applies this standard directly to tesamorelin users.

Red-Flag Stopping Criteria

Stop tesamorelin immediately and consult a physician if: fasting glucose exceeds 126 mg/dL on two separate readings; new or worsening edema appears in the hands or feet; or any new malignancy is diagnosed. Tesamorelin is absolutely contraindicated in active cancer because IGF-1 may promote tumor proliferation [2].

The Biohacker Stack: What Longevity Influencers Add to Tesamorelin

Tesamorelin rarely appears alone in longevity stacks. The most common co-interventions described in clinical commentary and telehealth records are below, with evidence levels labeled honestly.

Ipamorelin (GHRP Combination)

Ipamorelin is a selective growth hormone-releasing peptide (GHRP) that stimulates GH release through the ghrelin receptor. Combining a GHRH analog (tesamorelin) with a GHRP (ipamorelin) produces a synergistic GH pulse roughly double that of either agent alone, a pharmacodynamic observation confirmed in healthy adult studies using GHRH plus GHRP combinations [12]. Typical longevity doses are 200 to 300 mcg ipamorelin injected at the same time as tesamorelin before bed. Evidence level: pharmacodynamic RCT data for the GHRH-plus-GHRP class; ipamorelin-specific long-term safety data are limited to preclinical and small observational studies.

CJC-1295 No-DAC (Modified GRF 1-29)

CJC-1295 no-DAC (also called Modified GRF 1-29 or Mod-GRF) is a shorter GHRH fragment with a 30-minute half-life. Some practitioners use it as a lower-cost substitute for tesamorelin at 100 to 200 mcg per injection; others layer it with tesamorelin on alternate nights to reduce cost while preserving pulsatile stimulation. There are no head-to-head RCTs comparing CJC-1295 no-DAC directly to tesamorelin for VAT reduction. Evidence level: mechanistic and small-cohort observational.

Metformin (Metabolic Protection)

Some longevity physicians add metformin 500 mg with the evening meal to offset the mild glucose-raising effect of tesamorelin. The TAME (Targeting Aging with Metformin) trial, though not completed at time of writing, is evaluating metformin as a longevity intervention in non-diabetic adults [13]. Using metformin alongside tesamorelin is practitioner-reported and off-label; no trial has evaluated this combination prospectively.

Low-Dose Thyroid Optimization

Hypothyroidism attenuates GH secretion and IGF-1 response. Practitioners who find blunted IGF-1 response to tesamorelin despite adequate dose often check free T4 and consider low-dose levothyroxine or T3 augmentation. A 2003 JCEM study confirmed that thyroid hormone replacement in hypothyroid adults raises IGF-1 toward normal before any GH therapy is introduced [11]. This interaction is mechanistically sound; the clinical decision to add thyroid therapy still requires formal diagnosis of hypothyroidism.

Lifestyle Synergies That Are Not Optional

Sleep duration below seven hours per night blunts nocturnal GH pulses regardless of tesamorelin dose [10]. Resistance training two to four sessions per week raises baseline GH pulsatility and amplifies tesamorelin's IGF-1 response. Carbohydrate-restricted meals in the four hours before bed lower circulating somatostatin and are consistently recommended by clinicians using GH secretagogues, though this has not been tested in a tesamorelin-specific trial.

Safety Profile: What the Trials Recorded

Tesamorelin's adverse-event profile from the Phase III program is the most reliable guide available [4]:

• Injection site reactions: 25% of tesamorelin vs. 4% placebo (erythema, pruritis, pain)
• Peripheral edema: 6% vs. 2%
• Arthralgia: 13% vs. 8%
• Carpal tunnel syndrome: <1%, consistent with GH-class effects
• Fasting glucose elevation: small but statistically significant, not clinically significant at 26 weeks in the non-diabetic subset
• No signal for increased malignancy at 52 weeks, but the trials excluded patients with active cancer and were not powered for oncologic endpoints

The FDA label carries a warning that tesamorelin may impair glucose tolerance and should be used with caution in patients at high risk for diabetes [2]. HbA1c should be the primary glucose safety metric given that fasting glucose can fluctuate.

Off-Label Use, Compounding, and Legal Considerations

Egrifta is FDA-approved only for HIV-associated lipodystrophy. Using it for longevity optimization is off-label. Off-label prescribing is legal in the United States when a licensed physician determines it is medically appropriate [14]. Compounded tesamorelin from 503A or 503B pharmacies has been in a regulatory gray area since the FDA's 2023 guidance tightened rules around compounding of FDA-approved drug substances. Patients and prescribers should verify their compounding pharmacy's current regulatory status before ordering.

A 2023 FDA guidance document stated that "bulk drug substances used in compounding must appear on FDA's 503A or 503B bulks list, or the drug must not be commercially available in an appropriate dosage form" [14]. Tesamorelin is commercially available as Egrifta SV (2 mg/vial). Patients who can access branded Egrifta through specialty pharmacy with prior authorization for HIV lipodystrophy have the strongest regulatory footing; off-label compounded versions occupy more uncertain legal ground.

Expected Timeline of Outcomes

Based on the Phase III data and practitioner-reported experience, the following timeline is a reasonable expectation for healthy adults with excess visceral fat who run tesamorelin 2 mg nightly:

Weeks 1 to 4: No visible change in body composition; IGF-1 begins to rise within 2 weeks (confirmed in Phase III kinetic data) [4]. Some users report improved sleep quality and recovery, though this is anecdotal.

Weeks 4 to 12: Measurable VAT reduction on DEXA or MRI in most responders. The Phase III trials showed statistically significant VAT reduction by week 10 [4]. Scale weight may not change because lean mass may increase slightly.

Weeks 12 to 26: Peak VAT reduction. In Falutz 2010, the maximum effect at 2 mg was approximately 18% VAT reduction at 26 weeks [4]. Triglyceride improvement becomes apparent in those with baseline hypertriglyceridemia by week 12.

Post-cycle (weeks 27 to 34, off tesamorelin): Expect partial VAT rebound. Maintaining a caloric deficit and continuing resistance training attenuates rebound, though no controlled trial has quantified this attenuation in the longevity population.